AR085662A1 - Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia - Google Patents
Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemiaInfo
- Publication number
- AR085662A1 AR085662A1 ARP120100799A ARP120100799A AR085662A1 AR 085662 A1 AR085662 A1 AR 085662A1 AR P120100799 A ARP120100799 A AR P120100799A AR P120100799 A ARP120100799 A AR P120100799A AR 085662 A1 AR085662 A1 AR 085662A1
- Authority
- AR
- Argentina
- Prior art keywords
- hyperuricemia
- compositions
- methods
- disorders associated
- metabolic disorders
- Prior art date
Links
- 201000001431 Hyperuricemia Diseases 0.000 title abstract 4
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 abstract 1
- 229960004590 diacerein Drugs 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos y composiciones para el tratamiento y/o prevención de la hiperuricemia o trastornos metabólicos asociados a la hiperuricemia, que comprenden administrar a un paciente que lo necesita, una cantidad terapéuticamente efectiva de diacereína, reína, o una sal farmacéuticamente aceptable, un análogo, un profármaco o un metabolito activo de la misma.Reivindicación 6: El uso de acuerdo con la reivindicación 1, en el cual dicho medicamento comprende además por lo menos un agente terapéutico adicional seleccionado del grupo que consiste en agentes antiinflamatorios y agentes reductores de urato. Reivindicación 13: El uso de acuerdo con la reivindicación 10, en el cual dicho agente antiinflamatorio es seleccionado del grupo que consiste en fármacos antiinflamatorios no esteroides (AlNEs), corticosteroides, colchicinas y una combinación de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451600P | 2011-03-11 | 2011-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085662A1 true AR085662A1 (es) | 2013-10-16 |
Family
ID=46796094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100799A AR085662A1 (es) | 2011-03-11 | 2012-03-12 | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8865689B2 (es) |
| EP (1) | EP2683372B1 (es) |
| JP (1) | JP6012639B2 (es) |
| KR (1) | KR101567885B1 (es) |
| CN (1) | CN103429236B (es) |
| AR (1) | AR085662A1 (es) |
| AU (1) | AU2012229443B2 (es) |
| BR (1) | BR112013022332A2 (es) |
| CA (1) | CA2829101C (es) |
| ES (1) | ES2634562T3 (es) |
| IL (1) | IL228030B (es) |
| MX (1) | MX350666B (es) |
| PT (1) | PT2683372T (es) |
| RU (1) | RU2603050C2 (es) |
| TW (1) | TWI505827B (es) |
| WO (1) | WO2012125359A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102858155B (zh) * | 2010-04-08 | 2015-02-04 | 安成生物科技股份有限公司 | 使用双醋瑞因作为糖尿病的辅助治疗的方法 |
| BR112013022332A2 (pt) | 2011-03-11 | 2017-05-30 | Twi Biotechnology Inc | métodos para tratamento e/ou prevenção de hiperuricemia ou de um distúrbio metabólico associado com a hiperuricemia, e para melhorar o controle do nível de ácido úrico no sangue, e, composição farmacêutica |
| CN103638020A (zh) * | 2013-12-20 | 2014-03-19 | 中美华世通生物医药科技（武汉）有限公司 | 一种治疗痛风的新型药物组合物 |
| CN104491839B (zh) * | 2014-11-27 | 2016-06-22 | 青岛大学附属医院 | 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途 |
| KR101647348B1 (ko) * | 2014-12-30 | 2016-08-22 | 충남대학교산학협력단 | Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물 |
| JP2018513203A (ja) * | 2015-04-20 | 2018-05-24 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | ジアセレインを含有する製剤及びそれを用いて尿酸の血中濃度を低下させる方法 |
| US20160303050A1 (en) * | 2015-04-20 | 2016-10-20 | Twi Biotechnology, Inc. | Formulations containing diacerein and methods of lowering blood levels of uric acid using the same |
| TWI684465B (zh) * | 2015-04-22 | 2020-02-11 | 安成生物科技股份有限公司 | 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法 |
| CA2990948A1 (en) | 2015-07-01 | 2017-01-05 | Twi Biotechnology, Inc. | Diacerein or rhein topical formulations and uses thereof |
| MX2018002049A (es) * | 2015-08-17 | 2018-06-15 | Twi Biotechnology Inc | Diacereina o sus analogos para inhibir la expresion de proteina como mota relacionada a la apoptosis que contiene un dominio de reclutamiento de caspasa (asc), expresion de dominios de pirina y familia nlr que contienen 3 (nlrp3) y/o formacion de complejo de inflamasoma de nlrp3. |
| KR101863604B1 (ko) | 2016-04-08 | 2018-06-04 | 한국 한의학 연구원 | 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물 |
| TW201739448A (zh) * | 2016-05-06 | 2017-11-16 | 安成生物科技股份有限公司 | 用於治療及/或預防血液相關疾病之方法及配方 |
| CN107468955B (zh) * | 2017-09-06 | 2020-07-24 | 大连医科大学 | 治疗痛风性关节炎的中药及制备方法 |
| KR102361526B1 (ko) * | 2019-07-02 | 2022-02-11 | 한국 한의학 연구원 | 난각막을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물 |
| CN113082012A (zh) * | 2021-04-26 | 2021-07-09 | 北京亿药科技有限公司 | 紫苏烯在制备预防和/或治疗高尿酸血症药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04009698A (es) * | 2004-10-04 | 2006-04-05 | Maria Elena Garcia Armenta | Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam. |
| US7632490B2 (en) * | 2006-10-20 | 2009-12-15 | Regeneron Pharmaceuticals, Inc. | Use of IL-1 antagonists to treat gout |
| NZ575972A (en) * | 2006-10-20 | 2011-01-28 | Regeneron Pharma | Use of il-1 antagonists to treat gout and pseudogout |
| US8821924B2 (en) * | 2007-09-14 | 2014-09-02 | Wockhardt Ltd. | Rhein or diacerein compositions |
| US20100150938A1 (en) | 2008-07-03 | 2010-06-17 | University Of Massachusetts | Methods and compositions for reducing inflammation and treating inflammatory disorders |
| TWI473610B (zh) * | 2008-10-28 | 2015-02-21 | Twi Biotechnology Inc | 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物 |
| BR112013022332A2 (pt) | 2011-03-11 | 2017-05-30 | Twi Biotechnology Inc | métodos para tratamento e/ou prevenção de hiperuricemia ou de um distúrbio metabólico associado com a hiperuricemia, e para melhorar o controle do nível de ácido úrico no sangue, e, composição farmacêutica |
-
2012
- 2012-03-07 BR BR112013022332A patent/BR112013022332A2/pt not_active IP Right Cessation
- 2012-03-07 CN CN201280012914.9A patent/CN103429236B/zh not_active Expired - Fee Related
- 2012-03-07 KR KR1020137026784A patent/KR101567885B1/ko active IP Right Grant
- 2012-03-07 US US13/414,264 patent/US8865689B2/en not_active Expired - Fee Related
- 2012-03-07 MX MX2013010384A patent/MX350666B/es active IP Right Grant
- 2012-03-07 ES ES12757767.4T patent/ES2634562T3/es active Active
- 2012-03-07 EP EP12757767.4A patent/EP2683372B1/en not_active Not-in-force
- 2012-03-07 AU AU2012229443A patent/AU2012229443B2/en not_active Ceased
- 2012-03-07 WO PCT/US2012/027993 patent/WO2012125359A1/en active Application Filing
- 2012-03-07 CA CA2829101A patent/CA2829101C/en not_active Expired - Fee Related
- 2012-03-07 RU RU2013145498/14A patent/RU2603050C2/ru not_active IP Right Cessation
- 2012-03-07 PT PT127577674T patent/PT2683372T/pt unknown
- 2012-03-07 JP JP2013557816A patent/JP6012639B2/ja not_active Expired - Fee Related
- 2012-03-09 TW TW101108193A patent/TWI505827B/zh not_active IP Right Cessation
- 2012-03-12 AR ARP120100799A patent/AR085662A1/es unknown
-
2013
- 2013-08-19 IL IL228030A patent/IL228030B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| PT2683372T (pt) | 2017-10-25 |
| CA2829101A1 (en) | 2012-09-20 |
| RU2603050C2 (ru) | 2016-11-20 |
| TWI505827B (zh) | 2015-11-01 |
| JP6012639B2 (ja) | 2016-10-25 |
| IL228030B (en) | 2018-01-31 |
| RU2013145498A (ru) | 2015-04-20 |
| EP2683372A4 (en) | 2014-08-06 |
| CA2829101C (en) | 2019-08-20 |
| AU2012229443A1 (en) | 2013-09-12 |
| KR101567885B1 (ko) | 2015-11-10 |
| ES2634562T3 (es) | 2017-09-28 |
| CN103429236A (zh) | 2013-12-04 |
| WO2012125359A1 (en) | 2012-09-20 |
| US8865689B2 (en) | 2014-10-21 |
| AU2012229443B2 (en) | 2017-03-02 |
| KR20140019795A (ko) | 2014-02-17 |
| JP2014507476A (ja) | 2014-03-27 |
| NZ614486A (en) | 2014-11-28 |
| TW201249432A (en) | 2012-12-16 |
| US20120232044A1 (en) | 2012-09-13 |
| CN103429236B (zh) | 2016-09-21 |
| EP2683372B1 (en) | 2017-07-12 |
| MX2013010384A (es) | 2013-10-07 |
| IL228030A0 (en) | 2013-09-30 |
| BR112013022332A2 (pt) | 2017-05-30 |
| EP2683372A1 (en) | 2014-01-15 |
| MX350666B (es) | 2017-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| AR090601A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| CL2019003542A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| CL2017002939A1 (es) | Composiciones farmacéuticas tópicas | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| AR070047A1 (es) | Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog. | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| BR112015025424A2 (pt) | tratamento de câncer usando terapias de combinação de coenzima q10 | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| CO6280574A2 (es) | Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
| WO2014047288A3 (en) | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof | |
| ECSP12012352A (es) | Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal | |
| AR108793A1 (es) | Composiciones que comprenden timolol y un agente antiinflamatorio | |
| AR108792A1 (es) | Composiciones que comprenden timolol | |
| JP2019533018A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |